INDEMNITY AGREEMENTIndemnity Agreement • July 25th, 2024 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of [•], 2024, is made by and between Liminatus Pharma, Inc., a Delaware corporation (the “Company”), and [•] (“Indemnitee”).
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • June 14th, 2024 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances) • Delaware
THIS LICENSE AGREEMENT (“Agreement”) is entered into as of March 30, 2022 (the “Effective Date”), by and between InnoBation Bio Co., Ltd., a Korean company (“LICENSOR”) and Valetudo Therapeutics LLC, a Delaware company (“LICENSEE”).
ASSIGNMENT OF CONTRACTAssignment Agreement • June 14th, 2024 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances)
This Assignment Agreement is entered into as of October 1, 2022 by and between Valetudo Therapeutics LLC, a Delaware limited liability company (“Assignor”) and Liminatus Pharma, LLC, a Delaware limited liability company (“Assignee”) (the “Parties”).
ASSIGNMENT OF CONTRACTAssignment of Contract • June 14th, 2024 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances)
This Assignment is entered into as of April 10, 2020 by and between Viral Gene, Inc., a Delaware corporation (“Assignor”) and Liminatus Pharma, LLC, a Delaware limited liability company (“Assignee”) (the “Parties”).
Amendment to the LICENSE AND DEVELOPMENT AGREEMENT Between Targeted Diagnostics & Therapeutics, Inc. and Viral Gene, Inc. Dated September 8, 2016License and Development Agreement • June 14th, 2024 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances)
This Amendment (“Amendment’), effective November 1, 2016, is made by and between Targeted Diagnostics & Therapeutics, Inc. (“TDT”) and Viral Gene, Inc. (“VG”).
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • June 14th, 2024 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances)
THIS AGREEMENT, dated as of January l, 1999, is by and between THOMAS JEFFERSON UNIVERSITY (“.TJU”), a not-for-profit corporation, formed under the laws of the Commonwealth of Pennsylvania, and having its principal place of business at 11th and Walnut Streets, Philadelphia, Pennsylvania 19107, and Targeted Diagnostics & Therapeutics, Inc. (“TDT”), a corporation organized under the laws of the Commonwealth of Pennsylvania, and having its principal place of business at 728 Lancaster Avenue, Exton, PA 19341.
WAIVER AND CONSENTWaiver and Consent • November 8th, 2024 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances)
THIS WAIVER AND CONSENT (this “Waiver”), dated as of August 9, 2024, is executed by Iris Parent Holding Corp., a Delaware corporation (“ParentCo”), and Iris Acquisition Holdings LLC, a Delaware limited liability company (“Sponsor”).
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • November 8th, 2023 • Iris Parent Holding Corp. • Biological products, (no disgnostic substances) • Pennsylvania
THIS LICENSE AND DEVELOPMENT AGREEMENT (“Agreement”) is entered into as of June 10, 2018 (the “Effective Date”) between Liminatus Pharma, LLC, a Delaware limited liability company (“LIMINATUS”), and Targeted Diagnostics & Therapeutics, Inc. (“TDT”). LIMINATUS and TDT may each individually be referred to herein as a “Party” and may together be referred to herein as the “Parties.”
